Medications
Hormones
are drugs that can affect the growth of
prostate cancer cells.
Hormone therapy is sometimes used with radiation
treatment or surgery to help make sure that all cancer cells are
destroyed.
Chemotherapy
is the use of powerful
drugs—either injected or taken as pills—to destroy cancer cells. Many men
decide to have chemotherapy for treatment of late-stage prostate cancer, but
researchers are studying whether chemotherapy should be used before or after
surgery to treat early-stage, high-risk prostate cancer.11
American Cancer Society (2006). Cancer Facts and Figures 2006, pp. 1–56. Atlanta: American
Cancer Society. Available online: http://www.cancer.org/docroot/STT/stt_0.asp.
Kantoff PW (2007). Prostate cancer. In DC Dale, DD
Federman, eds., ACP Medicine, section 12, chap. 9. New
York: WebMD.
Gronberg H (2003). Prostate cancer epidemiology.
Lancet, 361(9360): 859–864.
U.S. Preventive Services Task Force (2003). Screening
for prostate cancer: Recommendations and rationale. American Family Physician, 67(4): 787–792.
National Institutes of Health (2007). Prostate cancer genetics: Fact sheet. Available online: http://www.nih.gov/about/researchresultsforthepublic.
Klein EA, et al. (2007). Epidemiology, etiology, and
prevention of prostate cancer. In AJ Wein et al., eds., Campbell-Walsh Urology, 9th ed., vol. 3, pp. 2854–2873.
Philadelphia: Saunders Elsevier.
Robbins C, et al. (2007). Confirmation study of
prostate cancer risk variants at 8q24 in African Americans identifies a novel
risk locus. Genome Research, 17(12):
1717–1722.
National Cancer Institute (2007). Prostate Cancer (PDQ): Prevention—Health Professional Version.
Available online:
http://www.nci.nih.gov/cancertopics/pdq/prevention/prostate/HealthProfessional.
Bill–Axelson A, et al. (2005). Radical prostatectomy
versus watchful waiting in early prostate cancer. New England Journal of Medicine, 352(19): 1977–1984.
Punglia RS, et al. (2003). Effect of verification bias
on screening for prostate cancer by measurement of prostate-specific antigen.
New England Journal of Medicine, 349(4):
335–342.
Scher HI, et al. (2005). Cancer of the prostate. In VT
DeVita Jr et al., eds., Cancer: Principles and Practice of Oncology, 7th ed., pp. 1192–1259. Philadelphia: Lippincott Williams
and Wilkins.
Badani KK, et al. (2007). Evolution of robotic radical
prostatectomy: Assessment after 2,766 procedures. Cancer, 110(9): 1951–1958.
Brada M, et al. (2007). Proton therapy in clinical
practice: Current clinical evidence. Journal of Clinical Oncology, 25(8): 965–970.
D'Amico AV, et al. (2007). Radiation therapy for
prostate cancer. In AJ Wein et al., eds., Campbell-Walsh Urology, 9th ed., vol. 3, pp. 3006–3031. Philadelphia: Saunders
Elsevier.
Iversen P, et al. (2004). Bicalutamide (150 mg) versus
placebo as immediate therapy alone or as adjuvant to therapy with curative
intent for early nonmetastatic prostate cancer: 5.3–year median followup from
the Scandinavian Prostate Cancer Group Study No. 6. Journal of Urology, 172(5, Part 1): 1871–1876.
Agency for Healthcare Research and Quality (2008).
Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer: Executive Summary (AHRQ Pub. No. 08-EHC010-1).
Rockville, MD: Agency for Healthcare Research and Quality. Available online:
http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=9&DocID=79.